Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivana Gojo

Showing results (81-90 of 122) with videos related to

Pageof 13
Sort By:
Leukemia Research|September 26, 2021
Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemiaHetty E Carraway, Yazeed Sawalha, Ivana Gojo, et al.
Leukemia Research|August 18, 2018
Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)Joshua F Zeidner, Matthew C Foster, Amanda L Blackford, et al.
Haematologica|May 30, 2015
Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemiaJoshua F Zeidner, Matthew C Foster, Amanda L Blackford, et al.
The Oncologist|July 27, 2024
Immune-related encephalitis after immune checkpoint inhibitor therapyMonica W Buckley, Aanika Balaji Warner, Julie Brahmer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 2, 2020
Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 PandemicElizabeth A Griffiths, Laura M Alwan, Kimo Bachiashvili, et al.
Biorxiv : the Preprint Server for Biology|September 2, 2025
A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AMLNour Sabiha Naji, Taha Ahmedna, J David Peske, et al.
Transplantation and Cellular Therapy|November 7, 2025
Long-Term Follow-Up of the Baltimore Experience with Hematopoietic Cell Transplantation for Severe Aplastic Anemia Using Post-Transplantation CyclophosphamideAmy E DeZern, Marianna Zahurak, Tyler Cavin, et al.
Leukemia|January 5, 2020
Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDSJoshua F Zeidner, Hanna A Knaus, Amer M Zeidan, et al.
Ejhaem|March 11, 2021
Increased body mass index is a risk factor for acute promyelocytic leukemiaSarah M Kashanian, Andrew Y Li, Moaath Mustafa Ali, et al.
Blood Cancer Discovery|November 15, 2021
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaJoshua F Zeidner, Benjamin G Vincent, Anastasia Ivanova, et al.
Pageof 13

Showing results (81-90 of 122) with videos related to

Sort By:
Pageof 13
Leukemia Research|September 26, 2021
Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemiaHetty E Carraway, Yazeed Sawalha, Ivana Gojo, et al.
Leukemia Research|August 18, 2018
Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)Joshua F Zeidner, Matthew C Foster, Amanda L Blackford, et al.
Haematologica|May 30, 2015
Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemiaJoshua F Zeidner, Matthew C Foster, Amanda L Blackford, et al.
The Oncologist|July 27, 2024
Immune-related encephalitis after immune checkpoint inhibitor therapyMonica W Buckley, Aanika Balaji Warner, Julie Brahmer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 2, 2020
Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 PandemicElizabeth A Griffiths, Laura M Alwan, Kimo Bachiashvili, et al.
Biorxiv : the Preprint Server for Biology|September 2, 2025
A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AMLNour Sabiha Naji, Taha Ahmedna, J David Peske, et al.
Transplantation and Cellular Therapy|November 7, 2025
Long-Term Follow-Up of the Baltimore Experience with Hematopoietic Cell Transplantation for Severe Aplastic Anemia Using Post-Transplantation CyclophosphamideAmy E DeZern, Marianna Zahurak, Tyler Cavin, et al.
Leukemia|January 5, 2020
Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDSJoshua F Zeidner, Hanna A Knaus, Amer M Zeidan, et al.
Ejhaem|March 11, 2021
Increased body mass index is a risk factor for acute promyelocytic leukemiaSarah M Kashanian, Andrew Y Li, Moaath Mustafa Ali, et al.
Blood Cancer Discovery|November 15, 2021
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaJoshua F Zeidner, Benjamin G Vincent, Anastasia Ivanova, et al.
Pageof 13